These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 7834457

  • 1. Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma.
    Vaglini M, Belli F, Santinami M, Arienti F, Parmiani G, Persiani L, Santoro N, Grazia Inglese M, D'Elia F, Cascinelli N.
    Ann Surg Oncol; 1995 Jan; 2(1):61-70. PubMed ID: 7834457
    [Abstract] [Full Text] [Related]

  • 2. Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study.
    Belli F, Arienti F, Rivoltini L, Santinami M, Mascheroni L, Prada A, Ammatuna M, Marchesi E, Parmiani G, Cascinelli N.
    Melanoma Res; 1992 Nov; 2(4):263-71. PubMed ID: 1490114
    [Abstract] [Full Text] [Related]

  • 3. Regional administration of lymphokine-activated killer cells can be superior to intravenous application.
    Keilholz U, Schlag P, Tilgen W, Brado B, Galm F, Görich J, Kauffmann GW, Möller P, Schneider S, Hunstein W.
    Cancer; 1992 Apr 15; 69(8):2172-5. PubMed ID: 1544123
    [Abstract] [Full Text] [Related]

  • 4. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases.
    Keilholz U, Scheibenbogen C, Brado M, Georgi P, Maclachlan D, Brado B, Hunstein W.
    Eur J Cancer; 1994 Apr 15; 30A(1):103-5. PubMed ID: 8142149
    [Abstract] [Full Text] [Related]

  • 5. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.
    Law TM, Motzer RJ, Mazumdar M, Sell KW, Walther PJ, O'Connell M, Khan A, Vlamis V, Vogelzang NJ, Bajorin DF.
    Cancer; 1995 Sep 01; 76(5):824-32. PubMed ID: 8625186
    [Abstract] [Full Text] [Related]

  • 6. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells.
    Bar MH, Sznol M, Atkins MB, Ciobanu N, Micetich KC, Boldt DH, Margolin KA, Aronson FR, Rayner AA, Hawkins MJ.
    J Clin Oncol; 1990 Jul 01; 8(7):1138-47. PubMed ID: 2358835
    [Abstract] [Full Text] [Related]

  • 7. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M, Clark JW, Smith JW, Steis RG, Urba WJ, Rubinstein LV, VanderMolen LA, Janik J, Sharfman WH, Fenton RG.
    J Natl Cancer Inst; 1992 Jun 17; 84(12):929-37. PubMed ID: 1629914
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.
    Gambacorti-Passerini C, Hank JA, Albertini MR, Borchert AA, Moore KH, Schiller JH, Bechhofer R, Borden EC, Storer B, Sondel PM.
    J Immunother Emphasis Tumor Immunol; 1993 Jan 17; 13(1):43-8. PubMed ID: 8435431
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Intraperitoneal lymphokine-activated killer-cell and interleukin-2 therapy for malignancies limited to the peritoneal cavity.
    Steis RG, Urba WJ, VanderMolen LA, Bookman MA, Smith JW, Clark JW, Miller RL, Crum ED, Beckner SK, McKnight JE.
    J Clin Oncol; 1990 Oct 17; 8(10):1618-29. PubMed ID: 2213099
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial.
    Dillman RO, Oldham RK, Barth NM, Birch R, Arnold J, West WH.
    J Natl Cancer Inst; 1990 Aug 15; 82(16):1345-9. PubMed ID: 2199682
    [Abstract] [Full Text] [Related]

  • 17. Treatment of advanced renal cell carcinoma using regional arterial administration of lymphokine-activated killer cells in combination with low doses of rIL-2.
    Hayakawa M, Hatano T, Ogawa Y, Gakiya M, Ogura H, Osawa A.
    Urol Int; 1994 Aug 15; 53(3):117-24. PubMed ID: 7645136
    [Abstract] [Full Text] [Related]

  • 18. Randomized study of interleukin 2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer.
    Koretz MJ, Lawson DH, York RM, Graham SD, Murray DR, Gillespie TM, Levitt D, Sell KM.
    Arch Surg; 1991 Jul 15; 126(7):898-903. PubMed ID: 1854252
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.